{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:40:14Z","timestamp":1792809614138,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40123-026-01478-y","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:31:22Z","timestamp":1788780682000},"page":"3603-3624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6155-0870","authenticated-orcid":false,"given":"Jelena","family":"Jovanovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zacharioudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Kalatzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarjuna","family":"Mulkalapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thom","family":"de Milliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"1478_CR1","first-page":"109","volume":"362","author":"J Liang","year":"2025","unstructured":"Liang J. Trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 2025;362:109.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1478_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","volume":"33","author":"PC Wu","year":"2019","unstructured":"Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3\u201313. https:\/\/doi.org\/10.1038\/s41433-018-0139-7.","journal-title":"Eye (Lond)"},{"issue":"4","key":"1478_CR3","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49. https:\/\/doi.org\/10.1167\/iovs.61.4.49.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1478_CR4","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","volume":"134","author":"JWL Tideman","year":"2016","unstructured":"Tideman JWL, Snabel MCC, Tedja MS, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134(12):1355\u201363. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.4009.","journal-title":"JAMA Ophthalmol"},{"key":"1478_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-325427","author":"J Liang","year":"1990","unstructured":"Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 1990. https:\/\/doi.org\/10.1136\/bjo-2024-325427.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1478_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03175-w","volume":"44","author":"L Sartor","year":"2024","unstructured":"Sartor L, Hunter DS, Vo ML, Samarawickrama C. Benefits and risks of orthokeratology treatment: a systematic review and meta-analysis. Int Ophthalmol. 2024;44(1):239. https:\/\/doi.org\/10.1007\/s10792-024-03175-w.","journal-title":"Int Ophthalmol"},{"issue":"12","key":"1478_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.66.12.39","volume":"66","author":"MA Bullimore","year":"2025","unstructured":"Bullimore MA, Saunders KJ, Baraas RC, et al. IMI\u2014interventions for controlling myopia onset and progression 2025. Invest Ophthalmol Vis Sci. 2025;66(12):39\u201339. https:\/\/doi.org\/10.1167\/iovs.66.12.39.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1478_CR8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.062.","journal-title":"Ophthalmology"},{"issue":"2","key":"1478_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031.","journal-title":"Ophthalmology"},{"issue":"1","key":"1478_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized double-blinded placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029.","journal-title":"Ophthalmology"},{"key":"1478_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014758.pub3","author":"JG Lawrenson","year":"2025","unstructured":"Lawrenson JG, Huntjens B, Virgili G, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2025. https:\/\/doi.org\/10.1002\/14651858.CD014758.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"1478_CR12","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1038\/s41433-023-02534-8","volume":"37","author":"G Zhang","year":"2023","unstructured":"Zhang G, Jiang J, Qu C. Myopia prevention and control in children: a systematic review and network meta-analysis. Eye (Lond). 2023;37(16):3461\u20139. https:\/\/doi.org\/10.1038\/s41433-023-02534-8.","journal-title":"Eye (Lond)"},{"issue":"11","key":"1478_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bjo-2025-327366","volume":"109","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, Jiang X, Chen R, Dong L. Efficacy comparison of atropine, orthokeratology and repeated low-level red-light therapy for myopia control in children: a systematic review and network meta-analysis. Br J Ophthalmol. 2025;109(11):1215\u201320. https:\/\/doi.org\/10.1136\/bjo-2025-327366.","journal-title":"Br J Ophthalmol"},{"key":"1478_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1478_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"2","key":"1478_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"AHJ Cipriani","year":"2013","unstructured":"Cipriani AHJ, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130\u20137. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008.","journal-title":"Ann Intern Med"},{"key":"1478_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","volume":"11","author":"JPNH Jansen","year":"2013","unstructured":"Jansen JPNH. Is network meta-analysis as valid as standard pairwise meta-analysis? it all depends on the distribution of effect modifiers. BMC Med. 2013;11:159. https:\/\/doi.org\/10.1186\/1741-7015-11-159.","journal-title":"BMC Med"},{"key":"1478_CR18","unstructured":"Higgins JPT TJ CJ, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions version 6.5. 2023. https:\/\/training.cochrane.org\/handbook\/current."},{"issue":"4","key":"1478_CR19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1167\/iovs.02-0816","volume":"44","author":"J Gwiazda","year":"2003","unstructured":"Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003;44(4):1492\u2013500. https:\/\/doi.org\/10.1167\/iovs.02-0816.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1478_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/APO.0000000000000609","volume":"12","author":"A Chia","year":"2023","unstructured":"Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D. Atropine ophthalmic solution to reduce myopia progression in pediatric subjects: the randomized, double-blind multicenter phase II APPLE study. Asia Pac J Ophthalmol. 2023;12(4):370\u20136.","journal-title":"Asia Pac J Ophthalmol"},{"issue":"5","key":"1478_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10384-023-01012-8","volume":"67","author":"O Hieda","year":"2023","unstructured":"Hieda O, Hiraoka T, Fujikado T, et al. Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children. Jpn J Ophthalmol. 2023;67(5):602\u201311.","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"1478_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, et al. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141(10):990\u20139.","journal-title":"JAMA Ophthalmol."},{"issue":"3","key":"1478_CR23","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","volume":"102","author":"J Loughman","year":"2024","unstructured":"Loughman J, Kobia-Acquah E, Lingham G, et al. Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024;102(3):e245\u201356. https:\/\/doi.org\/10.1111\/aos.15761.","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"1478_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamaophthalmol.2024.2295","volume":"142","author":"Z Wang","year":"2024","unstructured":"Wang Z, Li T, Zuo X, et al. 0.01% Atropine eye drops in children with myopia and intermittent exotropia: the AMIXT randomized clinical trial. JAMA Ophthalmol. 2024;142(8):722\u201330. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2295.","journal-title":"JAMA Ophthalmol"},{"key":"1478_CR25","unstructured":"ClinicalTrials.gov. The safety and efficacy of SYD-101 in children with myopia (STAR). https : \/\/clinicaltrials.gov\/study\/NCT03918915."},{"issue":"10","key":"1478_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/iovs.62.10.36","volume":"62","author":"LA Jones-Jordan","year":"2021","unstructured":"Jones-Jordan LA, Sinnott LT, Chu RH, et al. Myopia progression as a function of sex, age, and ethnicity. Invest Ophthalmol Vis Sci. 2021;62(10):36\u201336. https:\/\/doi.org\/10.1167\/iovs.62.10.36.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1478_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc B Stat Methodol. 2002;64(4):583\u2013639. https:\/\/doi.org\/10.1111\/1467-9868.00353.","journal-title":"J R Stat Soc B Stat Methodol"},{"key":"1478_CR28","unstructured":"Dias SWN, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials. National Institute for Health and Care Excellence (NICE); 2014."},{"issue":"8","key":"1478_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/psp4.12091","volume":"5","author":"D Mawdsley","year":"2016","unstructured":"Mawdsley D, Bennetts M, Dias S, Boucher M, Welton NJ. Model\u2010based network meta\u2010analysis: a framework for evidence synthesis of clinical trial data. CPT Pharmacomet Syst Pharmacol. 2016;5(8):393\u2013401.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"1478_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jval.2014.10.006","volume":"18","author":"RK Owen","year":"2015","unstructured":"Owen RK, Tincello DG, Keith RA. Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints. Value Health. 2015;18(1):116\u201326.","journal-title":"Value Health"},{"key":"1478_CR31","unstructured":"Dias S SA, Welton NJ, Ades AE. NICE DSU Technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment. 2011:76. https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-3-heterogeneity-subgroups-met\/."},{"issue":"4","key":"1478_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/ICL.0000000000000511","volume":"44","author":"JJ Walline","year":"2018","unstructured":"Walline JJ, Robboy MW, Hilmantel G, et al. Food and drug administration, american academy of ophthalmology, american academy of optometry, american association for pediatric ophthalmology and strabismus, american optometric association, american society of cataract and refractive surgery, and contact lens association of ophthalmologists co-sponsored workshop: controlling the progression of myopia: contact lenses and future medical devices. Eye Contact Lens. 2018;44(4):205\u201311.","journal-title":"Eye Contact Lens"},{"key":"1478_CR33","unstructured":"Core TR. A language and environment for statistical computing. R Foundation for Statistical Computing. 2023."},{"key":"1478_CR34","doi-asserted-by":"crossref","unstructured":"RStudio JSR. A platform-independent IDE for R and Sweave. J. Appl. Econ; 2012. p. 167\u2013172.","DOI":"10.1002\/jae.1278"},{"key":"1478_CR35","doi-asserted-by":"crossref","unstructured":"Dias SCD. Network meta-analysis explained. Arch Dis Child Fetal Neonatal Ed.; 2019. p. F8-F12.","DOI":"10.1136\/archdischild-2018-315224"},{"issue":"4","key":"1478_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"AHJ Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou AHJ, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082.","journal-title":"PLoS Med"},{"issue":"2","key":"1478_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"ASG Chaimani","year":"2012","unstructured":"Chaimani ASG. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3(2):161\u201376. https:\/\/doi.org\/10.1002\/jrsm.57.","journal-title":"Res Synth Methods"},{"key":"1478_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"SRG Balduzzi","year":"2023","unstructured":"Balduzzi SRG, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, Schwarzer G. netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106:1\u201340.","journal-title":"J Stat Softw"},{"issue":"1","key":"1478_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-03177-9","volume":"23","author":"NC Hansen","year":"2023","unstructured":"Hansen NC, Hvid-Hansen A, M\u00f8ller F, Bek T, Larsen DA, Jacobsen N, et al. Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety. BMC Ophthalmol. 2023;23(1):438.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"1478_CR40","first-page":"2181","volume":"15","author":"SK Agarwal","year":"2023","unstructured":"Agarwal SK, Saxena A, Saxena S. Evaluation of the safety and effectiveness of low-dose atropine eye drops in managing myopia progression among Indian children. Int J Pharm Clin Res. 2023;15(6):2181\u201392.","journal-title":"Int J Pharm Clin Res"},{"issue":"27","key":"1478_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007371","volume":"96","author":"YR Wang","year":"2017","unstructured":"Wang YR, Bian HL, Wang Q. Atropine 0.5% eyedrops for the treatment of children with low myopia: a randomized controlled trial. Med (Baltimore). 2017;96(27):e7371. https:\/\/doi.org\/10.1097\/MD.0000000000007371.","journal-title":"Med (Baltimore)"},{"key":"1478_CR42","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2147\/OPTH.S66884","volume":"8","author":"T Fujikado","year":"2014","unstructured":"Fujikado T, Ninomiya S, Kobayashi T, Suzaki A, Nakada M, Nishida K. Effect of low-addition soft contact lenses with decentered optical design on myopia progression in children: a pilot study. Clin Ophthalmol. 2014;8:1947\u201356. https:\/\/doi.org\/10.2147\/OPTH.S66884.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1478_CR43","first-page":"180","volume":"21","author":"MY Yen","year":"1989","unstructured":"Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989;21(5):180\u20132.","journal-title":"Ann Ophthalmol"},{"issue":"1","key":"1478_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.1999.15.85","volume":"15","author":"Y-F Shih","year":"1999","unstructured":"Shih Y-F, Chen C-H, Chou A-C, Ho T-C, Lin LL-K, Hung P-T. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999;15(1):85\u201390.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"4","key":"1478_CR45","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00417-023-06301-z","volume":"262","author":"W Lin","year":"2024","unstructured":"Lin W, Li N, Liu J, Zhang B, Wei R. Relative corneal refractive power shift and inter-eye differential axial growth in children with myopic anisometropia treated with bilateral orthokeratology. Graefes Arch Clin Exp Ophthalmol. 2024;262(4):1203\u201313.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1478_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2021.101537","volume":"46","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Sun X, Chen Y. Controlling anisomyopia in children by orthokeratology: a one-year randomised clinical trial. Contact Lens Anterior Eye. 2023;46(1):101537.","journal-title":"Contact Lens Anterior Eye"},{"key":"1478_CR47","unstructured":"Santen. Clinical Study Report: a placebo-controlled, double-masked comparative study of DE-127 ophthalmic solution in Myopia - Phase II\/III Confirmatory Study - (Protocol No.: 012702LT). 2023."},{"issue":"6","key":"1478_CR48","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2020.10834","volume":"324","author":"JJ Walline","year":"2020","unstructured":"Walline JJ, Walker MK, Mutti DO, et al. Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. JAMA. 2020;324(6):571\u201380. https:\/\/doi.org\/10.1001\/jama.2020.10834.","journal-title":"JAMA"},{"issue":"2","key":"1478_CR49","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1167\/iovs.11-7769","volume":"53","author":"DA Berntsen","year":"2012","unstructured":"Berntsen DA, Sinnott LT, Mutti DO, Zadnik K. A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation. Invest Ophthalmol Vis Sci. 2012;53(2):640\u20139. https:\/\/doi.org\/10.1167\/iovs.11-7769.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1478_CR50","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1167\/iovs.10-6631","volume":"52","author":"Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group","year":"2011","unstructured":"Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive-addition lenses versus single-vision lenses for slowing progression of myopia in children with high accommodative lag and near esophoria. Invest Ophthalmol Vis Sci. 2011;52(5):2749\u201357. https:\/\/doi.org\/10.1167\/iovs.10-6631.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"1478_CR51","first-page":"470","volume":"73","author":"GW Fulk","year":"2002","unstructured":"Fulk GW, Cyert LA, Parker DE. A randomized clinical trial of bifocal glasses for myopic children with esophoria: results after 54 months. Optometry. 2002;73(8):470\u20136.","journal-title":"Optometry"},{"issue":"S200","key":"1478_CR52","first-page":"1","volume":"69","author":"H Jensen","year":"1991","unstructured":"Jensen H. Myopia progression in young school children. a prospective study of myopia progression and the effect of a trial with bifocal lenses and beta blocker eye drops. Acta Ophthalmologica. 1991;69(S200):1\u201379.","journal-title":"Acta Ophthalmologica"},{"issue":"7","key":"1478_CR53","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1167\/iovs.03-1306","volume":"45","author":"JE Gwiazda","year":"2004","unstructured":"Gwiazda JE, Hyman L, Norton TT, et al. Accommodation and related risk factors associated with myopia progression and their interaction with treatment in COMET children. Invest Ophthalmol Vis Sci. 2004;45(7):2143\u201351.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1478_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/tvst.13.5.12","volume":"13","author":"X Chen","year":"2024","unstructured":"Chen X, Guo Y, Bi H, et al. The impact of back optic zone design in orthokeratology on visual performance. Transl Vis Sci Technol. 2024;13(5):12\u201312.","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"1478_CR55","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/opo.12834","volume":"41","author":"B Guo","year":"2021","unstructured":"Guo B, Cheung SW, Kojima R, Cho P. One-year results of the Variation of Orthokeratology Lens Treatment Zone (VOLTZ) Study: a prospective randomised clinical trial. Ophthalmic Physiol Opt. 2021;41(4):702\u201314. https:\/\/doi.org\/10.1111\/opo.12834.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"1","key":"1478_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2022.101745","volume":"46","author":"JK Lau","year":"2023","unstructured":"Lau JK, Wan K, Cho P. Orthokeratology lenses with increased compression factor (OKIC): a 2-year longitudinal clinical trial for myopia control. Cont Lens Anterior Eye. 2023;46(1):101745.","journal-title":"Cont Lens Anterior Eye"},{"issue":"1","key":"1478_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2022.101755","volume":"46","author":"N Li","year":"2023","unstructured":"Li N, Lin W, Zhang K, Li B, Su Q, Du B, et al. The effect of back optic zone diameter on relative corneal refractive power distribution and corneal higher-order aberrations in orthokeratology. Contact Lens Anterior Eye. 2023;46(1):101755.","journal-title":"Contact Lens Anterior Eye"},{"issue":"6","key":"1478_CR58","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/opo.13213","volume":"43","author":"T Liu","year":"2023","unstructured":"Liu T, Chen C, Ma W, Yang B, Wang X, Liu L. One\u2010year results for myopia control with aspheric base curve orthokeratology lenses: a prospective randomised clinical trial. Ophthalmic Physiol Opt. 2023;43(6):1469\u201377.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"3","key":"1478_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030447","volume":"10","author":"M Loertscher","year":"2021","unstructured":"Loertscher M, Backhouse S, Phillips JR. Multifocal orthokeratology versus conventional orthokeratology for myopia control: a paired-eye study. J Clin Med. 2021;10(3):447.","journal-title":"J Clin Med"},{"issue":"5","key":"1478_CR60","doi-asserted-by":"publisher","first-page":"770","DOI":"10.18240\/ijo.2023.05.15","volume":"16","author":"W-T Tang","year":"2023","unstructured":"Tang W-T, Zhang L, Zhang H-D, Li S-B, Liang H. Orthokeratology with increased compression factor in adolescent myopia control: a 2-year prospective randomized clinical trial. Int J Ophthalmol. 2023;16(5):770.","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"1478_CR61","doi-asserted-by":"publisher","first-page":"324","DOI":"10.18240\/ijo.2024.02.15","volume":"17","author":"W-T Tang","year":"2024","unstructured":"Tang W-T, Luo X-N, Zhao W-J, Liao J, Xu X-Y, Zhang H-D, et al. One-year results for myopia control of orthokeratology with different back optic zone diameters: a randomized trial using a novel multispectral-based topographer. Int J Ophthalmol. 2024;17(2):324.","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"1478_CR62","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/02713683.2020.1820528","volume":"46","author":"X Yang","year":"2021","unstructured":"Yang X, Bi H, Li L, Li S, Chen S, Zhang B, et al. The effect of relative corneal refractive power shift distribution on axial length growth in myopic children undergoing orthokeratology treatment. Curr Eye Res. 2021;46(5):657\u201365.","journal-title":"Curr Eye Res"},{"key":"1478_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102256","author":"S-C Lee","year":"2024","unstructured":"Lee S-C, Hsu M-Y, Huang S-C, Chen C. Soft peripheral contact lens for eye elongation control (SPACE): 1-year results of a double-blinded randomized controlled trial. Contact Lens Anterior Eye. 2024. https:\/\/doi.org\/10.1016\/j.clae.2024.102256.","journal-title":"Contact Lens Anterior Eye"},{"issue":"3","key":"1478_CR64","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10792-020-01658-0","volume":"41","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Hao Q. Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children. Int Ophthalmol. 2021;41(3):1011\u20137. https:\/\/doi.org\/10.1007\/s10792-020-01658-0.","journal-title":"Int Ophthalmol"},{"issue":"12","key":"1478_CR65","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/ICL.0000000000001043","volume":"49","author":"T Peng","year":"2023","unstructured":"Peng T, Jiang J. Efficiency and related factors of multifocal soft contact lenses in controlling myopia. Eye Contact Lens. 2023;49(12):535\u201341.","journal-title":"Eye Contact Lens"},{"issue":"2","key":"1478_CR66","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/children11020177","volume":"11","author":"M\u00c1 S\u00e1nchez-Tena","year":"2024","unstructured":"S\u00e1nchez-Tena M\u00c1, Cleva JM, Villa-Collar C, et al. Effectiveness of a spectacle lens with a specific asymmetric myopic peripheral defocus: 12-month results in a Spanish population. Children. 2024;11(2):177.","journal-title":"Children"},{"issue":"3","key":"1478_CR67","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/09286586.2023.2232462","volume":"31","author":"H Zhang","year":"2024","unstructured":"Zhang H, Yang P, Li Y, Zhang W, Li S. Effect of low-concentration atropine eye drops in controlling the progression of Myopia in children: a one-and two-year follow-up study. Ophthalmic Epidemiol. 2024;31(3):240\u20138.","journal-title":"Ophthalmic Epidemiol"},{"issue":"11","key":"1478_CR68","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.ophtha.2024.05.015","volume":"131","author":"RWW Xiong","year":"2024","unstructured":"Xiong RWW, Tang X, et al. Myopia control effect of repeated low-level red-light therapy combined with orthokeratology: a multicenter randomized controlled trial. Ophthalmology. 2024;131(11):1304\u201313.","journal-title":"Ophthalmology"},{"issue":"3","key":"1478_CR69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65(3):315\u201325. https:\/\/doi.org\/10.1007\/s10384-021-00822-y.","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"1478_CR70","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of Myopia 2: Myopia control with Atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.004.","journal-title":"Ophthalmology"},{"issue":"3","key":"1478_CR71","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, et al. Three-year clinical trial of low-concentration atropine for Myopia Progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology. 2022;129(3):308\u201321. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.002.","journal-title":"Ophthalmology"},{"issue":"5","key":"1478_CR72","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/OPX.0000000000002249","volume":"102","author":"DSA Horn","year":"2025","unstructured":"Horn DSA, Jenewein EC, et al. Topical review: potential mechanisms of atropine for myopia control. Optom Vis Sci. 2025;102(5):260\u201370. https:\/\/doi.org\/10.1097\/OPX.0000000000002249.","journal-title":"Optom Vis Sci"},{"issue":"1","key":"1478_CR73","doi-asserted-by":"publisher","first-page":"2644577","DOI":"10.1155\/joph\/2644577","volume":"2026","author":"QYJ Jiang","year":"2026","unstructured":"Jiang QYJ, Cao X, Mou L. Navigating the core challenges of atropine therapy in Myopia: a mechanistic and clinical analysis of dose, response, and durability. J Ophthalmol. 2026;2026(1):2644577. https:\/\/doi.org\/10.1155\/joph\/2644577.","journal-title":"J Ophthalmol"},{"issue":"1","key":"1478_CR74","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4274572","volume":"2021","author":"C Chen","year":"2021","unstructured":"Chen C, Yao J. Efficacy and adverse effects of atropine for myopia control in children: a meta\u2010analysis of randomised controlled trials. J Ophthalmol. 2021;2021(1):4274572.","journal-title":"J Ophthalmol"},{"key":"1478_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014758.pub2","author":"JG Lawrenson","year":"2023","unstructured":"Lawrenson JG, Shah R, Huntjens B, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023. https:\/\/doi.org\/10.1002\/14651858.CD014758.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1478_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17496","author":"DC Schmidt","year":"2025","unstructured":"Schmidt DC, Hvid\u2010Hansen A, Jacobsen N, et al. Efficacy of interventions for myopia control in children: a systematic review with network meta\u2010analyses. Acta Ophthalmol. 2025. https:\/\/doi.org\/10.1111\/aos.17496.","journal-title":"Acta Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01478-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:04:29Z","timestamp":1792807469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01478-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01478-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Frederic Ernst and Thom de Milliano are employees of Santen Pharmaceuticals. Jelena Jovanovi\u0107, Maria Zacharioudaki, Georgios Papadakis, Marilena Kalatzi, and Nagarjuna Mulkalapalli are employees of IQVIA, a vendor contracted to develop methods, generate statistical models, support statistical analyses, and provide editorial assistance in the development of the manuscript on behalf of Santen Pharmaceuticals.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}